<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471289</url>
  </required_header>
  <id_info>
    <org_study_id>PADI/200601</org_study_id>
    <nct_id>NCT00471289</nct_id>
  </id_info>
  <brief_title>PTA and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia</brief_title>
  <acronym>PADI</acronym>
  <official_title>Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Netherlands Society for Interventional Radiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Netherlands Society for Interventional Radiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the performance of paclitaxel-coated balloon
      expandable stainless steel coronary stent for the treatment of infrapopliteal stenoses and
      occlusions in patients with critical limb ischemia compared to percutaneous transluminal
      balloon angioplasty (PTA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critical limb ischemia (CLI) is a serious condition that is becoming more and more common in
      the western world due to the growing percentage of elderly in the population and the rising
      incidence of diabetes. In about 40% of patients a stenosis or occlusion in the arteries below
      the level of the knee will be present. Restoration of blood flow is imperative to allow pain
      relief and tissue healing. Without revascularization patients with CLI are at risk for limb
      loss and potentially fatal complications such as sepsis.

      In patients treated with percutaneous transluminal balloon angioplasty (PTA)significant
      restenosis is found in approximately 50% after 6 months.

      In interventional cardiology a significant reduction in restenosis rates in coronary arteries
      has been found using drug eluting stents (DES), including the paclitaxel eluting stent
      (TAXUS, Boston Scientific). DES locally deliver drugs (e.g. paclitaxel) that interfere with
      the restenosis process.

      Using DES in treating below the knee (infrapopliteal) arterial lesions in patients with CLI
      may improve patency and clinical outcome.

      Comparison:

      Treatment of below the knee arterial lesions in patients with CLI with PTA and DES compared
      to only PTA.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be primary patency of the treated site at 6 months. Primary patency is defined as &lt;50% loss of luminal diameter at the treated site on CT arteriography (CTA) without re-intervention in the interim.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary patency of the treated sites at 3, 6 and 12 months after intervention assessed by duplex sonography (binary patency, &lt;50% stenosis defined as PSV ratio &lt;2.0)</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation of the treated ischemic leg at 3, 6 and 12 months.</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major amputation (at or above the ankle) of the trial leg at 3, 6 and 12 months</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor amputation (below the ankle excluding the toes) of the trial leg at 3, 6 and 12 months.</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infrapopliteal surgical bypass of the trial leg at 3, 6 and 12 months.</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infrapopliteal endovascular re-intervention of the trial leg at 3, 6 and 12 months.</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural (within 30 days) complications.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death.</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment primarily by Rutherford score for peripheral arterial disease</measure>
    <time_frame>2, 3, 4 and 5 years after treatment</time_frame>
    <description>Clinical assessment outpatient clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion patency by means of duplex sonography</measure>
    <time_frame>2, 3, 4 and 5 years after treatment</time_frame>
    <description>During outpatient clinic visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major amputation (at or above the ankle) of treated limb</measure>
    <time_frame>yearly up to 10 years after treatment</time_frame>
    <description>Assessment up to 5 years after treatment during outpatient clinic visits From 5 to 10 years by means of yearly evaluation of patient charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor amputation (below the ankle excluding the toes) of the trial leg at 3, 6 and 12 months.</measure>
    <time_frame>yearly up to 10 years after treatment</time_frame>
    <description>From 2 to 5 years during outpatient clinic visits From 5 to 10 years yearly evaluation of patient charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endovascular or surgical re-intervention of target lesion</measure>
    <time_frame>3, 6, 12 months, 2,3,4 and 5 years after inclusion</time_frame>
    <description>Follow-up until first re-intervention of target lesion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTA with primary placement of Drug (paclitaxel) Eluting Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA with placement of paclitaxel-eluting stent</intervention_name>
    <description>PTA with placement of paclitaxel-eluting stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA</intervention_name>
    <description>PTA</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age &gt; 18 years

          -  If female patient with child bearing potential, patient may not be pregnant at the
             study entry and must utilize reliable birth control for the duration of her
             participation into the study

          -  Patient is willing and able to comply with the specified follow-up evaluation

          -  Critical Limb Ischaemia, this is Fontaine stage III (ischaemic rest pain) and IV
             (ischaemic ulcers or gangrene) or Rutherford category 4 (ischaemic rest pain), 5
             (minor tissue loss) or 6 (major tissue loss)

          -  Stenotic (&gt;50% luminal loss) or occluded infrapopliteal artery, including the
             tibiofibular trunk, the anterior tibial artery, the posterior tibial artery and the
             peroneal artery, with a lesion length â‰¤ 60 mm

          -  Artery to be treated with a diameter more tham or equal to 2mm and less than or equal
             to 4mm

          -  Patent common iliac, external iliac, superficial femoral and popliteal artery on the
             ipsilateral side prior to randomisation, possibly after treatment during the same
             session

          -  At least one patent crural (anterior tibial, posterior tibial or peroneal) artery with
             expected unobstructed runoff to ankle level after treatment

        Exclusion Criteria:

          -  Acute limb ischaemia

          -  Subacute limb ischaemia which requires thrombolysis as first treatment modality

          -  Active bleeding or bleeding diathesis

          -  Recent (less than 3 months) hemorrhagic stroke or other any other CNS abnormality with
             increased risk of haemorrhage, such as intracranial neoplasm, arteriovenous
             malformation, intracranial aneurysm or aneurysm repair

          -  Gastrointestinal or genitourinary bleeding of clinical significance within the
             previous 6 weeks before treatment

          -  Aneurysm in common femoral, superficial femoral or popliteal artery on the ipsilateral
             side

          -  Revascularization involving the same limb within 30 days prior to the index procedure
             or planned revascularization of the same limb within 30 days of the index procedure

          -  Previous implanted stent at the index site

          -  Life expectancy of less than 6 months or other factors making clinical follow-up
             difficult

          -  Known allergy to acetylsalicylic acid (aspirin), clopidogrel, heparin or paclitaxel

          -  Known allergy to contrast media

          -  Known heparin induced thrombocytopenia (HIT type 2)

          -  Patient unable or unwilling to tolerate anticoagulant, anti-platelet therapy or
             contrast media

          -  Creatinine clearance &lt; 20 ml/min (as derived from Cockcroft-Gault or MDRD
             formula)unless patient is on hemodialysis

          -  Aneurysm in common femoral, superficial femoral or popliteal artery on the ipsilateral
             side

          -  Severely calcified lesions with expected resistance to stenting

          -  Poor inflow due to ipsilateral stenoses or occlusions of the iliac or femoropopliteal
             arteries that cannot be treated during the same session

          -  Significant vessel tortuosity or other parameters prohibiting access to the lesions
             and/or delivery of the stent

          -  Patients without (expected) distal runoff to the index site

          -  Previous implanted stent at the index site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Van Overhagen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HagaZiekenhuis Dept. of Radiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis, location Leyweg</name>
      <address>
        <city>The Hague</city>
        <state>ZH</state>
        <zip>2545CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMCU)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Section D: chronic critical limb ischaemia. Eur J Vasc Endovasc Surg. 2000 Jun;19 Suppl A:S144-243. Review.</citation>
    <PMID>10957907</PMID>
  </reference>
  <reference>
    <citation>Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H; BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005 Dec 3;366(9501):1925-34.</citation>
    <PMID>16325694</PMID>
  </reference>
  <reference>
    <citation>Jensen SA, Vatten LJ, Myhre HO. The prevalence of chronic critical lower limb ischaemia in a population of 20,000 subjects 40-69 years of age. Eur J Vasc Endovasc Surg. 2006 Jul;32(1):60-5. Epub 2006 Mar 2.</citation>
    <PMID>16513377</PMID>
  </reference>
  <reference>
    <citation>Black JH 3rd, LaMuraglia GM, Kwolek CJ, Brewster DC, Watkins MT, Cambria RP. Contemporary results of angioplasty-based infrainguinal percutaneous interventions. J Vasc Surg. 2005 Nov;42(5):932-9.</citation>
    <PMID>16275450</PMID>
  </reference>
  <reference>
    <citation>Sigala F, Menenakos Ch, Sigalas P, Baunach Ch, Langer S, Papalambros E, Hepp W. Transluminal angioplasty of isolated crural arterial lesions in diabetics with critical limb ischemia. Vasa. 2005 Aug;34(3):186-91.</citation>
    <PMID>16184838</PMID>
  </reference>
  <reference>
    <citation>Hynes N, Mahendran B, Manning B, Andrews E, Courtney D, Sultan S. The influence of subintimal angioplasty on level of amputation and limb salvage rates in lower limb critical ischaemia: a 15-year experience. Eur J Vasc Endovasc Surg. 2005 Sep;30(3):291-9.</citation>
    <PMID>15939635</PMID>
  </reference>
  <reference>
    <citation>Eskelinen E, AlbÃ¤ck A, Roth WD, Lappalainen K, Keto P, Railo M, Eskelinen A, LepÃ¤ntalo M. Infra-inguinal percutaneous transluminal angioplasty for limb salvage: a retrospective analysis in a single center. Acta Radiol. 2005 Apr;46(2):155-62.</citation>
    <PMID>15902890</PMID>
  </reference>
  <reference>
    <citation>Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg. 2005 Mar;41(3):423-35; discussion 435.</citation>
    <PMID>15838475</PMID>
  </reference>
  <reference>
    <citation>Atar E, Siegel Y, Avrahami R, Bartal G, Bachar GN, Belenky A. Balloon angioplasty of popliteal and crural arteries in elderly with critical chronic limb ischemia. Eur J Radiol. 2005 Feb;53(2):287-92.</citation>
    <PMID>15664294</PMID>
  </reference>
  <reference>
    <citation>Tsetis D, Belli AM. The role of infrapopliteal angioplasty. Br J Radiol. 2004 Dec;77(924):1007-15. Review.</citation>
    <PMID>15569642</PMID>
  </reference>
  <reference>
    <citation>Matsagas MI, Rivera MA, Tran T, Mitchell A, Robless P, Davies AH, Geroulakos G. Clinical outcome following infra-inguinal percutaneous transluminal angioplasty for critical limb ischemia. Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):251-5.</citation>
    <PMID>14562973</PMID>
  </reference>
  <reference>
    <citation>Molloy KJ, Nasim A, London NJ, Naylor AR, Bell PR, Fishwick G, Bolia A, Thompson MM. Percutaneous transluminal angioplasty in the treatment of critical limb ischemia. J Endovasc Ther. 2003 Apr;10(2):298-303.</citation>
    <PMID>12877613</PMID>
  </reference>
  <reference>
    <citation>Haider SN, Kavanagh EG, Forlee M, Colgan MP, Madhavan P, Moore DJ, Shanik GD. Two-year outcome with preferential use of infrainguinal angioplasty for critical ischemia. J Vasc Surg. 2006 Mar;43(3):504-512.</citation>
    <PMID>16520164</PMID>
  </reference>
  <reference>
    <citation>Wiskirchen J, SchÃ¶ber W, Schart N, Kehlbach R, Wersebe A, Tepe G, Claussen CD, Duda SH. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol. 2004 Sep;39(9):565-71.</citation>
    <PMID>15308939</PMID>
  </reference>
  <reference>
    <citation>Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006 Feb 2;354(5):483-95. Review.</citation>
    <PMID>16452560</PMID>
  </reference>
  <reference>
    <citation>Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K, Schiele F, Russell ME, Koglin J, Serruys PW; TAXUS II Study Group. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation. 2005 Dec 20;112(25):3876-83. Epub 2005 Dec 12.</citation>
    <PMID>16344384</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2007</study_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Netherlands Society for Interventional Radiology</investigator_affiliation>
    <investigator_full_name>H. van Overhagen MD PhD</investigator_full_name>
    <investigator_title>Radiologist Haga Teaching Hospital The Hague</investigator_title>
  </responsible_party>
  <keyword>Critical Limb Ischemia</keyword>
  <keyword>Stents</keyword>
  <keyword>Drug Eluting Stents</keyword>
  <keyword>Peripheral arterial disease</keyword>
  <keyword>PAD</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>TAXUS</keyword>
  <keyword>Infrapopliteal</keyword>
  <keyword>Infragenicular</keyword>
  <keyword>Interventional Radiology</keyword>
  <keyword>CLI</keyword>
  <keyword>DES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

